Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
DTaP Vaccine A-Jiangsu Province Centers for Disease Control and Prevention-pertussis-diphtheria-tetanus
- Development stage
- Unknown
- Lead developer
- Beijing Minhai Biological
- Modality
- Vaccines & Immunotherapeutics
- Administration
- Intramuscular
01
Overview
DTaP Vaccine A is an adsorbed diphtheria, tetanus, and acellular pertussis (DTaP) vaccine developed by Beijing Minhai Biological Co., Ltd. It is designed for the active immunization of infants and children against three major infectious diseases: pertussis (whooping cough), diphtheria, and tetanus. The vaccine utilizes acellular pertussis components, which typically include purified pertussis toxoid (PT) and filamentous hemagglutinin (FHA), to provide a safer profile with fewer side effects compared to older whole-cell pertussis (DTwP) vaccines. It is administered as a multi-dose primary series. In clinical trials sponsored by the Jiangsu Province Centers for Disease Control and Prevention, this specific formulation was evaluated for immunogenicity and safety in healthy infants aged 3 to 5 months.
- Other names
- Adsorbed Diphtheria, Tetanus and Acellular Pertussis Vaccine (Minhai)Minhai DTaP vaccine
02
Targets
Diphtheria toxinFHA (Filamentous hemagglutinin)
Beyond the preview
Go deeper on DTaP Vaccine A-Jiangsu Province Centers for Disease Control and Prevention-pertussis-diphtheria-tetanus.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on DTaP Vaccine A-Jiangsu Province Centers for Disease Control and Prevention-pertussis-diphtheria-tetanus.